Boston type 1 keratoprosthesis: the New York Eye and Ear experience

Patel, Amar; Wu, Elaine; Ritterband, David C.; Seedor, John A.

doi:10.1038/eye.2011.325

Cited by 74 publications

(66 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Using the same VA criterion (0.05), Verdejo-Gomez et al [16] found a success rate of 83% (n = 12). Using 0.10 VA, but with different follow-up times, Greiner et al [14 ]had success in 89% (n = 36 at 1 year), Bradley et al [4] in 77% (n = 30), Aldave et al [17] in 68% (n = 27 at 1 year), Goldman et al [18] in 63% (n = 107), Zerbe et al [12 ]in 57% (n = 141) and Patel et al [19] in 43% (n = 50) of cases. This shows that our VA success rate is consistent with previous reports.…”

Section: Discussionmentioning

confidence: 99%

Influence of Primary Diagnosis and Complications on Visual Outcome in Patients Receiving a Boston Type 1 Keratoprosthesis

Nascimento

Paz²,

Rosandic³

et al. 2014

Ophthalmic Res

View full text Add to dashboard Cite

Purpose: To analyse how primary diagnosis and complications affect the evolution of post-operative visual acuity (VA). Methods: We performed retrospective chart analysis on 59 eyes in 57 patients with various diagnoses, most of which were non-standard indications for Boston type 1 keratoprosthesis (Kpro) implantation. The follow-up period was at least 3 months. Patients were classified based on the evolution of post-operative VA: group A demonstrated stable VA improvement, group B lost VA improvement and group C no significant VA improvement. Results: We assigned 46% of our cases to group A with stable VA improvement, 32% to group B with lost VA improvement, and 22% to group C with no VA improvement. The number of graft failures before Kpro implantation did not influence VA outcome. Except for the relatively good VA outcome in chemical burn and radiation injury patients, there seems to be no association between primary diagnosis and positive or negative VA outcome. Only 9% of patients with posterior segment complications and 20% with infections and associated pathologies were assigned to group A. Conclusion: Most cases (78%) showed improvement in VA after Boston type 1 Kpro (groups A and B). Posterior segment complications and infections mostly resulted in persistent loss of vision. These complications should be prevented and carefully treated.

show abstract

Section: Discussionmentioning

confidence: 99%

Influence of Primary Diagnosis and Complications on Visual Outcome in Patients Receiving a Boston Type 1 Keratoprosthesis

Nascimento

Paz²,

Rosandic³

et al. 2014

Ophthalmic Res

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6][7][8] The US Food and Drug Administration cleared the device for use in 1992, and prior to 2004, less than 100 devices had been implanted. As of M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 3 keratoprosthesis procedures or permanent keratoprosthesis using devices other than Boston type 1 KPro were also excluded.…”

Section: Introductionmentioning

confidence: 99%

Predictors of Visual Outcomes Following Boston Type 1 Keratoprosthesis Implantation

Ahmad

Akpek

Gehlbach

et al. 2015

American Journal of Ophthalmology

View full text Add to dashboard Cite

“…6,15,41,51,75,76,79 Case series with more than 50 eyes have consistently reported incidence rates of approximately 50%. 2,3,47,67 In one of the largest series, consisting of 265 eyes, the incidence was 31.7%. 78 The time interval between surgery and development of RPM varies from weeks to months, with appearance as early as 1 week and as late as 49 months.…”

Section: Retroprosthetic Membranementioning

confidence: 97%

“…2 Despite treatment, many RPMs recur with rates approaching 65%, and some eyes require multiple treatments. 2,67,76 Hence, research has focused on methods of preventing RPM formation. Several Boston KPro design modifications, such as a threadless KPro 76 and devices with titanium backplates, may reduce risk of RPM formation.…”

Section: Retroprosthetic Membranementioning

confidence: 99%